Wang et al., demonstrated a 36% increase in γ-H2AX-positive CTCs from patients with a variety of different solid tumor malignancies (breast, colorectal, small cell lung and prostate cancers) enrolled in a variety of Phase I clinical trials of chemotherapy with and without PARP inhibitors. Here, H2AX is linked to prostate cancer.